INmune Bio, Inc.
XPro1595
Alzheimer's disease
Resolved
35days ago
Phase 2 readout · Jun 2, 2026
What's at stake
Phase 2 trial results for XPro1595 in Alzheimer's disease are due Jun 2, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer’s Trial”